Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30796075 | 1.00 | MAPT (0.61) | MAPTMCHR1NPC1RAB9APOLB | |
| SCHEMBL30795540 | 0.90 | MAPT (0.56) | MAPTMCHR1NPC1RAB9APOLB | |
| SCHEMBL970262 | 0.90 | MAPT (0.56) | MAPTMCHR1NPC1RAB9APOLB | |
| SCHEMBL30794894 | 0.90 | LMNA (0.49) | MAPTMCHR1NPC1RAB9APOLB | |
| SCHEMBL969579 | 0.90 | LMNA (0.49) | MAPTMCHR1NPC1RAB9APOLB | |
| SCHEMBL968586 | 0.82 | NAPEPLD (0.47) | MAPTMCHR1NPC1RAB9APOLB | |
| SCHEMBL30796192 | 0.82 | MAPT (0.56) | MAPTNPC1RAB9APOLBLMNA | |
| SCHEMBL969430 | 0.82 | MAPT (0.56) | MAPTNPC1RAB9APOLBLMNA | |
| SCHEMBL973838 | 0.80 | WNT3A (0.50) | MAPTLMNAALDH1A1HPGDGAA | |
| SCHEMBL30795276 | 0.80 | WNT3A (0.52) | POLBALDH1A1KDM4EHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298766-B1 | Pharmaceutical formulations comrpising a substituted pyridine derivative | LUNDBECK & CO AS H (DK) | 2013-09-18 | — | — | EP | claimed |
| US-8299071-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | claimed |
| EP-2298766-A1 | Substituted pyridine derivatives | H. Lundbeck A/S (DK) | 2011-03-23 | — | — | EP | claimed |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-01-06 | — | — | US | claimed |
| US-7812020-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2010-10-12 | — | — | US | claimed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| US-20080318953-A1 | Substituted Pyridine Derivatives | H. LUNDBECK A/S (DK) | 2008-12-25 | — | — | US | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2298766-B1 | Pharmaceutical formulations comrpising a substituted pyridine derivative | LUNDBECK & CO AS H (DK) | 2013-09-18 | — | — | EP | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-8299071-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-7812020-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2010-10-12 | — | — | US | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| US-20080318953-A1 | Substituted Pyridine Derivatives | H. LUNDBECK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| EP-1983974-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | KCNQ4, KCNQ5, KCNQ1 | MAPT 1786/4885MCHR1 2703/4885NPC1 539/4885 |
| US-20080318953-A1 | Substituted Pyridine Derivatives | KCNQ2, KCNQ1, KCNQ5 | MAPT 1188/4885MCHR1 3437/4885NPC1 666/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | MAPT 1260/4885MCHR1 443/4885NPC1 402/4885 |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | KCNQ2, KCNQ1, KCNQ5 | MAPT 1133/4885MCHR1 2972/4885NPC1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.